'I've Hit My Goal, So I'm Done': The Case Against Stopping a Working Drug
A woman who reached her target weight on semaglutide wants to stop — a request that runs directly into the trial data on what happens after GLP-1 therapy is discontinued.
Camille D., a 44-year-old elementary school librarian, walked into her one-year follow-up visit noticeably lighter than the photo on her old badge and asked, before she'd even sat down, when she could stop the injections. She'd started semaglutide fourteen months ago at a BMI of 36, alongside a genuine, sustained effort at the walking routine her physician had suggested, and has lost 19% of her starting body weight — a figure at the upper end of what STEP 1's own participants reached on this dose, which makes her a strong responder rather than a typical one, and a result she is visibly, understandably proud of, and one she has started describing to friends as 'fixed.' She'd already told her sister she was planning to stop, and had, by her own account, been quietly counting down to this appointment for weeks.
The word 'fixed' is doing more work in that sentence than the pharmacology actually supports, and it's the reason today's visit isn't the simple congratulations-and-taper conversation Camille was expecting. The STEP 1 trial's own extension data followed patients who discontinued semaglutide after a comparable period of treatment and found the weight didn't stay off on its own — roughly two-thirds of what had been lost returned within the following year, and the blood pressure and lipid improvements that had traveled alongside the weight loss reversed along with it. Camille's blood pressure, which had come down from a consistent 138/88 to 118/74 over her fourteen months of treatment, is part of what's actually being discussed when the question is whether to stop.
In follow-up, a goal reached and a question about what comes next
I want to walk through the actual data with her before we agree to stop, because 'I've hit my goal so I'm done' is a reasonable instinct built on a mistaken premise. The STEP 1 extension study followed patients who discontinued semaglutide after a year of treatment and found they regained roughly two-thirds of their lost weight within the following year, along with a real reversal of the metabolic improvements — blood pressure, lipids, glycemic markers — that had accompanied the weight loss itself.
That data is right, and I don't want to undersell it, but I think the framing matters for how she hears it. Obesity behaves, physiologically, like other chronic diseases we don't expect a patient to 'graduate' from — hypertension doesn't stay controlled once a patient stops their antihypertensive either. The honest comparison isn't 'stopping a course of antibiotics' but 'stopping a maintenance medication for a chronic condition,' and reframing it that way changes what stopping actually means to her.
Agreed, and I'd offer her a middle path rather than a binary stop-or-continue: a supervised dose reduction rather than outright discontinuation, watching her weight and metabolic markers closely as we taper. Some patients maintain much of their result on a lower maintenance dose than the one that got them to goal, though the data on that specific strategy is thinner than the discontinuation data itself, and I'd tell her that honestly rather than promise a result I can't back with the same trial evidence.
If a genuine dose reduction still triggers meaningful regain for her specifically, that itself is useful information — it would argue for staying at the effective dose rather than accepting a slow return to where she started.
Agreed: rather than full discontinuation, trial a supervised dose reduction with close monitoring of weight and metabolic markers, explicitly framed to Camille as maintenance therapy for a chronic condition rather than a course to be completed and stopped.
Not fully agreed, and left open for the next several visits to actually answer: whether Camille will tolerate the lower dose without meaningful regain, or whether her own physiology will argue for returning to the dose that got her to goal. Both physicians told her plainly that the dose-reduction strategy has thinner trial support than the discontinuation data itself, and that her own response over the coming months, not a guess made today, would settle it.